Risk acceptance in multiple sclerosis patients on natalizumab treatment.
<h4>Objective</h4>We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.<h4>Methods</h4>From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a co...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/840274e7d6b24193b1129c06899c0145 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:840274e7d6b24193b1129c06899c0145 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:840274e7d6b24193b1129c06899c01452021-11-18T08:42:38ZRisk acceptance in multiple sclerosis patients on natalizumab treatment.1932-620310.1371/journal.pone.0082796https://doaj.org/article/840274e7d6b24193b1129c06899c01452013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24340060/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.<h4>Methods</h4>From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.<h4>Results</h4>No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). In low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.<h4>Conclusions</h4>Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits.Carmen TurMar TintoréÁngela Vidal-JordanaDenis BichuettiPablo Nieto GonzálezMaría Jesús ArévaloGeorgina ArrambideElisenda AngladaIngrid GalánJoaquín CastillóCarlos NosJordi RíoMaría Isabel MartínManuel ComabellaJaume Sastre-GarrigaXavier MontalbanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 12, p e82796 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Carmen Tur Mar Tintoré Ángela Vidal-Jordana Denis Bichuetti Pablo Nieto González María Jesús Arévalo Georgina Arrambide Elisenda Anglada Ingrid Galán Joaquín Castilló Carlos Nos Jordi Río María Isabel Martín Manuel Comabella Jaume Sastre-Garriga Xavier Montalban Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| description |
<h4>Objective</h4>We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.<h4>Methods</h4>From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.<h4>Results</h4>No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). In low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.<h4>Conclusions</h4>Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits. |
| format |
article |
| author |
Carmen Tur Mar Tintoré Ángela Vidal-Jordana Denis Bichuetti Pablo Nieto González María Jesús Arévalo Georgina Arrambide Elisenda Anglada Ingrid Galán Joaquín Castilló Carlos Nos Jordi Río María Isabel Martín Manuel Comabella Jaume Sastre-Garriga Xavier Montalban |
| author_facet |
Carmen Tur Mar Tintoré Ángela Vidal-Jordana Denis Bichuetti Pablo Nieto González María Jesús Arévalo Georgina Arrambide Elisenda Anglada Ingrid Galán Joaquín Castilló Carlos Nos Jordi Río María Isabel Martín Manuel Comabella Jaume Sastre-Garriga Xavier Montalban |
| author_sort |
Carmen Tur |
| title |
Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| title_short |
Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| title_full |
Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| title_fullStr |
Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| title_full_unstemmed |
Risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| title_sort |
risk acceptance in multiple sclerosis patients on natalizumab treatment. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/840274e7d6b24193b1129c06899c0145 |
| work_keys_str_mv |
AT carmentur riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT martintore riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT angelavidaljordana riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT denisbichuetti riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT pablonietogonzalez riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT mariajesusarevalo riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT georginaarrambide riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT elisendaanglada riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT ingridgalan riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT joaquincastillo riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT carlosnos riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT jordirio riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT mariaisabelmartin riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT manuelcomabella riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT jaumesastregarriga riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment AT xaviermontalban riskacceptanceinmultiplesclerosispatientsonnatalizumabtreatment |
| _version_ |
1718421391684927488 |